CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing

BACKGROUND: Chimeric antigen receptor (CAR)-based T cell therapy is in early clinical trials to target the neuroectodermal tumor, neuroblastoma. No preclinical or clinical efficacy data are available for retinoblastoma to date. Whereas unilateral intraocular retinoblastoma is cured by enucleation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Andersch, Lena, Radke, Josefine, Klaus, Anika, Schwiebert, Silke, Winkler, Annika, Schumann, Elisa, Grunewald, Laura, Zirngibl, Felix, Flemmig, Carina, Jensen, Michael C., Rossig, Claudia, Joussen, Antonia, Henssen, Anton, Eggert, Angelika, Schulte, Johannes H., Künkele, Annette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732842/
https://www.ncbi.nlm.nih.gov/pubmed/31500597
http://dx.doi.org/10.1186/s12885-019-6131-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732842/
https://www.ncbi.nlm.nih.gov/pubmed/31500597
http://dx.doi.org/10.1186/s12885-019-6131-1

Ejemplares similares